Best use of adjuvant systemic therapies II, chemotherapy aspects: Dose of chemotherapy-cytotoxicity, duration and responsiveness

Breast

Volumn 12, Issue 6, 2003, Pages 529-537

  Bergh, Jonas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Dosage; Dose dense; Dose intensity; Human; Total dose

Indexed keywords

CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DNA MICROARRAY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HUMAN; LEUKOPENIA; LYMPHATIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; OPTIMAL DRUG DOSE; PATIENT SELECTION; PRIORITY JOURNAL; VOMITING;

EID: 0348149062     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00162-0     Document Type: Article

References (61)

1. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist L E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-919.
2. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
3. EBCTCG. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
4. EBCTCG. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196.
5. Schwartzmann G, Ratain M, Cragg G M et al. Anticancer drug discovery and development throughout the world. J Clin Oncol 2002; 20 (Suppl.): 475-595.
6. Bergh J. Where next with stem-cell-supported high-dose therapy for breast cancer? [comment]. Lancet 2000; 355: 944-945.
7. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611.
8. Gurney H, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998; 16: 2299-2304.
9. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677-1684.
10. Baker S D, Verweij J, Rowinsky E K et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991 2001. J Nat Cancer Inst 2002; 94: 1883-8.
11. Piccart M J, Biganzoli L, Di Leo A. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 2000; 36 (Suppl 1): S4-S10.
12. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomized trial involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
13. Antman K, Gale R. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570-574.
14. Antman K, Eder J, Elias A, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 1990; 17: 33-38.
15. Eder J, Elias A, Shea T et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-1245.
16. Ljungman P, Bjorkstrand B, Fornander T et al. High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. Bone Marrow Transplant 1998; 22: 445-448.
17. Ayash L, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14: 2984-2992.
18. Bergh J. High-dose therapy with autologous bone marrow stem cell support in primary, metastatic human breast cancer - A review. Acta Oncol 1995; 34: 669-674.
19. Bergh J. Is there a role for intensive therapy in breast cancer? Acta Oncol 1999; 38 Suppl 13: 37-46.
20. Lindman H, Wiklund T Holte H et al. FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group. Acta Oncol 1999; 38: 239-45.
21. Antman K, Rowlings P, Vaughan W et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
22. Rahman Z, Frye D, Buzdar A et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-3177.
23. Stadtmauer E A, O'Neill A, Goldstein L J et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group see [comments]. N Engl J Med 2000; 342: 1069-1076.
24. Gluck S, Crump M, Stewart D et al. A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemotherapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study, ECCO 11 the European Cancer Conference, Lisbon, 21-25 October, 2001; Eur J Cancer, 2001; 37 (Suppl 6).
25. Tannock I, Boyd N, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-1387.
26. Engelsman E, Klijn J, Rubens R et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC breast cancer co-operative group phase III trial (10808). Eur J Cancer 1991; 27: 966-970.
27. Goldhirsch A, Coates A, Colleoni M, Castiglione-Gertsch M, Gelber R. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 1998; 16: 1358-1362.
28. Colleoni M, Rocca A, Sandri M T et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80.
29. Bonadonna G, Rossi A, Tancini G et al. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan. Cancer Treat Rep 1981; 65(Suppl 1): 61-65.
30. Colleoni M, Pricer K, Catiglione-Gertsch M et al. Dose response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 1998; 34: 1693-1700.
31. Wood W, Budman D, Korzun A et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma [published erratum appears in N Engl J Med 1994; 331: 139]. N Engl J Med 1994; 330: 1253-1259.
32. Budman D, Berry D, Cirrincione C et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211.
33. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997; 75: 301-305.
34. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF [see comments]. Br J Cancer 1999; 80: 1763-1766.
35. Cameron D, Massie C, Kerr G, Leonard R. Neutropenia with adjuvant CMF: is it a marker of effective dosing? Third European Breast Cancer Conference, Barcelona, March 19-23, 2002.
36. Paridaens R, Wildiers J, Dumez H et al. Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): a retrospective analysis, 27th ESMO Congress, Vol. 13, Oxford: Nice, 18-22 October 2002. Oxford: Oxford University Press, 2002.
37. Sandström M, Freijs A, Larsson R et al. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581-1588.
38. Bergh J. Tailored chemotherapy to equal toxicity - is it possible? In: Senn H-J, Gelber R, Goldhirsch A, Thürlimann B, eds. Adjuvant Therapy of Primary Breast Cancer. Berlin, Heidelberg, New York: Springer-Verlag, 1998: 328-340.
39. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study [In Process Citation]. Lancet 2000; 356: 1384 1391.
40. Levine M, Bramwell V, Pritchard K et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658.
41. Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21: 298-305.
42. Citron M, Berry D, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741 /cancer and leukemia group B trial 9741. J Clin Oncol 2003; 21: 1431-1439.
43. Hendersson I C, Berry D A, Demetri G D et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
44. Coombes R, Bliss J, Wils J et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996; 14: 35-45.
45. French Epirubicin Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19:602-611.
46. Di Leo A, Larsimont D, Beauduin M et al. CMF or anthracycline-based adjuvant chemotherapy for node-positive (N+) breast cancer (BC) patients (PTS): 4 year results of a Belgian randomised clinical trial with predictive markers analysis. Thirty-Fifth Annual Meeting of American Society of Clinical Oncology, Vol. 18, Atlanta, GA, May 15-18, 1999. American Society of Clinical Oncology, 1999.
47. Fisher B, Anderson S, Wickerham D et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-1869.
48. Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17: 3374-3388.
49. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-15.
50. Nicto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 2003; 88: 201-211.
51. Rodenhuis S, Bontelbal M, Beex L et al. High dose chemotherapy with stem cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
52. Peters W, Rosner G, Vredenburgh J et al. Updated results of a prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13, Thirty-Seventh Annual Meeting of American Society of Clinical Oncology, Vol. 20. San Francisco, CA, May 12-15, 2001. American Society of Clinical Oncology, 2001.
53. Perou C, Sörlie T, Eisen M et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
54. Sorlie T, Perou C M, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
55. West M, Blanchette C, Dressman H et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001; 98: 11462-11467.
56. Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 5979-5984.
57. Hedenfalk I, Duggan D, Chen Y et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-548.
58. van't Veer L J, Dai H, van de Vijver M J et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
59. van de Vijver M J, He YD, van't Veer L J et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
60. Bjohle J, Pawitan Y, Skoog L et al. Microarray studies on a population based breast cancer cohort - search for gene profiles with prognostic and predictive value, 25th Annual San Antonio Breast Cancer Symposium, Vol. 76, suppl 1, San Antonio, USA, December 11-14, 2002. Dordrecht: Kluwer Academic Publishers, 2002.
61. Poikonen P. Chemotherapy of breast cancer with special emphasis on the white bloodcell count, amenorrhoea. Department of Oncology, University of Helsinki, Helsinki, 2001: 1-55.